1. Home
  2. ECOR vs ADVM Comparison

ECOR vs ADVM Comparison

Compare ECOR & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECOR
  • ADVM
  • Stock Information
  • Founded
  • ECOR 2005
  • ADVM 2006
  • Country
  • ECOR United States
  • ADVM United States
  • Employees
  • ECOR N/A
  • ADVM N/A
  • Industry
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ECOR Health Care
  • ADVM Health Care
  • Exchange
  • ECOR Nasdaq
  • ADVM Nasdaq
  • Market Cap
  • ECOR 39.7M
  • ADVM 47.4M
  • IPO Year
  • ECOR 2018
  • ADVM 2014
  • Fundamental
  • Price
  • ECOR $7.75
  • ADVM $2.70
  • Analyst Decision
  • ECOR Strong Buy
  • ADVM Strong Buy
  • Analyst Count
  • ECOR 2
  • ADVM 5
  • Target Price
  • ECOR $25.50
  • ADVM $23.80
  • AVG Volume (30 Days)
  • ECOR 118.8K
  • ADVM 276.3K
  • Earning Date
  • ECOR 08-06-2025
  • ADVM 08-11-2025
  • Dividend Yield
  • ECOR N/A
  • ADVM N/A
  • EPS Growth
  • ECOR N/A
  • ADVM N/A
  • EPS
  • ECOR N/A
  • ADVM N/A
  • Revenue
  • ECOR $26,458,000.00
  • ADVM $1,000,000.00
  • Revenue This Year
  • ECOR $23.21
  • ADVM N/A
  • Revenue Next Year
  • ECOR $44.10
  • ADVM $18.82
  • P/E Ratio
  • ECOR N/A
  • ADVM N/A
  • Revenue Growth
  • ECOR 41.54
  • ADVM N/A
  • 52 Week Low
  • ECOR $4.47
  • ADVM $1.78
  • 52 Week High
  • ECOR $19.49
  • ADVM $8.58
  • Technical
  • Relative Strength Index (RSI)
  • ECOR 64.43
  • ADVM 54.36
  • Support Level
  • ECOR $6.57
  • ADVM $2.57
  • Resistance Level
  • ECOR $7.80
  • ADVM $2.85
  • Average True Range (ATR)
  • ECOR 0.74
  • ADVM 0.21
  • MACD
  • ECOR 0.03
  • ADVM 0.02
  • Stochastic Oscillator
  • ECOR 63.97
  • ADVM 62.42

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: